Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · IEX Real-Time Price · USD
48.38
+0.36 (0.75%)
At close: Jul 19, 2024, 4:00 PM
48.35
-0.03 (-0.06%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Keros Therapeutics Employees
Keros Therapeutics had 136 employees as of December 31, 2023. The number of employees increased by 31 or 29.52% compared to the previous year.
Employees
136
Change (1Y)
31
Growth (1Y)
29.52%
Revenue / Employee
$1,721
Profits / Employee
-$1,178,691
Market Cap
1.75B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 136 | 31 | 29.52% |
Dec 31, 2022 | 105 | 45 | 75.00% |
Dec 31, 2021 | 60 | 25 | 71.43% |
Dec 31, 2020 | 35 | 12 | 52.17% |
Dec 31, 2019 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Evotec SE | 4,952 |
Galapagos NV | 1,123 |
Veracyte | 815 |
Supernus Pharmaceuticals | 652 |
RxSight | 374 |
Harmony Biosciences Holdings | 246 |
Neumora Therapeutics | 124 |
Ligand Pharmaceuticals | 58 |
KROS News
- 26 days ago - Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth - Benzinga
- 4 weeks ago - Keros Therapeutics Announces Leadership Updates - GlobeNewsWire
- 5 weeks ago - Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association - GlobeNewsWire
- 7 weeks ago - Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors - GlobeNewsWire
- 2 months ago - Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association - GlobeNewsWire
- 2 months ago - Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference - GlobeNewsWire
- 5 months ago - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire